Vor Biopharma Inc.
VOR Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2020โFY2025
Last close ยท Oct 23, 2026
$18.26
3.6%
Revenue
Total sales reported in the income statement.
โ
vs prior year
Operating margin
Operating income as a share of revenue.
โ
Net income
Profit after all expenses, interest and tax.
โ$696M
Free cash flow
Cash from operations minus capital spending.
โ$144M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
$992M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
0.1x
On $179.68 EPS (TTM)
What Vor Biopharma Inc. does
No business description yet.
- Legal name
- Vor Biopharma Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Mar 30, 2026
- Accession ยท CIK
- 0001193125-26-130451
0001817229
Revenue and margins
Vor Biopharma Inc. had โ of revenue in fiscal 2025.
FY20
Revenue โ
FY21
Revenue โ
FY22
Revenue โ
FY23
Revenue โ
FY24
Revenue โ
FY25
Revenue โ
FY20
Gross โ
Operating โ
Net โ
FCF โ
FY21
Gross โ
Operating โ
Net โ
FCF โ
FY22
Gross โ
Operating โ
Net โ
FCF โ
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross โ
Operating โ
Net โ
FCF โ
FY25
Gross โ
Operating โ
Net โ
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY20
Net income โ$43.3M
FY21
Net income โ$68.9M
FY22
Net income โ$92.1M
FY23
Net income โ$118M
FY24
Net income โ$117M
FY25
Net income โ$696M
Q3 '23
Net income โ$33.2M
Q4 '23
Net income โ$26.3M
Q1 '24
Net income โ$30.8M
Q2 '24
Net income โ$27.8M
Q3 '24
Net income โ$27.6M
Q4 '24
Net income โ$30.7M
Q1 '25
Net income โ$32.5M
Q2 '25
Net income โ$1.6B
Q3 '25
Net income โ$813M
Q4 '25
Net income $1.7B
Q1 '26
Net income โ$220M
Q2 '26
Net income โ$62.8M
FY20
Diluted EPS โ$230.57
FY21
Diluted EPS โ$2.10
FY22
Diluted EPS โ$2.33
FY23
Diluted EPS โ$1.75
FY24
Diluted EPS โ$34.03
FY25
Diluted EPS โ$70.50
Q3 '23
Diluted EPS โ$0.49
Q4 '23
Diluted EPS โ$0.38
Q1 '24
Diluted EPS โ$0.45
Q2 '24
Diluted EPS โ$0.41
Q3 '24
Diluted EPS โ$8.05
Q4 '24
Diluted EPS โ$25.12
Q1 '25
Diluted EPS โ$5.21
Q2 '25
Diluted EPS โ$251.24
Q3 '25
Diluted EPS โ$121.63
Q4 '25
Diluted EPS $307.58
Q1 '26
Diluted EPS โ$5.11
Q2 '26
Diluted EPS โ$1.16
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY20
Return on capital โ
Return on equity โ
Return on assets โ57.1%
FY21
Return on capital โ
Return on equity โ87.7%
Return on assets โ43.3%
FY22
Return on capital โ
Return on equity โ39.5%
Return on assets โ34.0%
FY23
Return on capital โ
Return on equity โ58.7%
Return on assets โ47.4%
FY24
Return on capital โ
Return on equity โ94.5%
Return on assets โ68.6%
FY25
Return on capital โ
Return on equity โ
Return on assets โ229.3%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$144M in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
FY20
Free cash flow โ$40.5M
FY21
Free cash flow โ$73.0M
FY22
Free cash flow โ$93.6M
FY23
Free cash flow โ$101M
FY24
Free cash flow โ$99.9M
FY25
Free cash flow โ$144M
Q3 '23
Free cash flow โ$28.4M
Q4 '23
Free cash flow โ$24.1M
Q1 '24
Free cash flow โ$30.6M
Q2 '24
Free cash flow โ$21.9M
Q3 '24
Free cash flow โ$23.3M
Q4 '24
Free cash flow โ$24.1M
Q1 '25
Free cash flow โ$31.3M
Q2 '25
Free cash flow โ$35.3M
Q3 '25
Free cash flow โ$53.9M
Q4 '25
Free cash flow โ$23.1M
Q1 '26
Free cash flow โ$38.3M
Q2 '26
Free cash flow โ$25.5M
FY20
Cash from operations โ$36.3M
Capital spending $4.2M
FY21
Cash from operations โ$69.1M
Capital spending $3.9M
FY22
Cash from operations โ$85.1M
Capital spending $8.5M
FY23
Cash from operations โ$100M
Capital spending $1.1M
FY24
Cash from operations โ$99.7M
Capital spending $0.2M
FY25
Cash from operations โ$143M
Capital spending $0.9M
Cash from operations
Capital spending
Q3 '23
Cash from operations โ$27.9M
Capital spending $0.5M
Q4 '23
Cash from operations โ$24.0M
Capital spending $0.1M
Q1 '24
Cash from operations โ$30.5M
Capital spending $0.1M
Q2 '24
Cash from operations โ$21.8M
Capital spending $0.0M
Q3 '24
Cash from operations โ$23.3M
Capital spending $0.0M
Q4 '24
Cash from operations โ$24.1M
Capital spending $0.1M
Q1 '25
Cash from operations โ$31.1M
Capital spending $0.2M
Q2 '25
Cash from operations โ$35.2M
Capital spending $0.2M
Q3 '25
Cash from operations โ$53.7M
Capital spending $0.2M
Q4 '25
Cash from operations โ$22.8M
Capital spending $0.3M
Q1 '26
Cash from operations โ$38.2M
Capital spending $0.0M
Q2 '26
Cash from operations โ$25.4M
Capital spending $0.1M
Cash from operations
Capital spending
Dividends, buybacks and share count
Vor Biopharma Inc. returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 187.3%.
FY20
Dividends $0.0M
Buybacks โ
FY21
Dividends $0.0M
Buybacks โ
FY22
Dividends $0.0M
Buybacks โ
FY23
Dividends $0.0M
Buybacks โ
FY24
Dividends $0.0M
Buybacks โ
FY25
Dividends $0.0M
Buybacks โ
Dividends
Buybacks
FY20
Diluted shares 0.00B
FY21
Diluted shares 0.03B
FY22
Diluted shares 0.04B
FY23
Diluted shares 0.07B
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.01B
Balance sheet
Cash, debt and the ratios that show how comfortably Vor Biopharma Inc. can carry it.
FY20
Cash $48.5M
Debt โ
FY21
Cash $207M
Debt โ
FY22
Cash $230M
Debt โ
FY23
Cash $137M
Debt โ
FY24
Cash $91.9M
Debt โ
FY25
Cash $455M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $207M | $230M | $137M | $91.9M | $455M |
| Current ratio | 21.1x | 18.1x | 9.0x | 5.2x | 18.2x |
| Quick ratio | 21.1x | 18.1x | 9.0x | 5.2x | 18.2x |
| Total assets | $243M | $299M | $198M | $143M | $464M |
| Total liabilities | $26.3M | $48.8M | $47.4M | $46.2M | $628M |
| Shareholders' equity | $216M | $251M | $151M | $96.7M | โ$164M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 6 | โ / 6 | โ / 6 | โ / 6 | โ / 6 |
| Accruals ratio | โ9.3% | 0.2% | โ2.6% | โ7.1% | โ10.1% | โ182.3% |
| Altman Z'' | โ5.35 | 10.49 | 5.78 | โ2.39 | โ10.35 | โ7.63 |
6 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Research and development | $31.6M | $47.5M | $64.6M | $94.3M | $93.3M | $322M |
| Operating income | โ$43.4M | โ$69.0M | โ$93.4M | โ$126M | โ$121M | โ$372M |
| Net income | โ$43.3M | โ$68.9M | โ$92.1M | โ$118M | โ$117M | โ$696M |
| Net income to common | โ$49.3M | โ$70.1M | โ$92.1M | โ$118M | โ | โ |
| Diluted EPS | โ$230.57 | โ$2.10 | โ$2.33 | โ$1.75 | โ$34.03 | โ$70.50 |
| Diluted shares | 0.00B | 0.03B | 0.04B | 0.07B | 0.00B | 0.01B |
| Cash flow | ||||||
| Cash from operations | โ$36.3M | โ$69.1M | โ$85.1M | โ$100M | โ$99.7M | โ$143M |
| Capital expenditure | $4.2M | $3.9M | $8.5M | $1.1M | $0.2M | $0.9M |
| Free cash flow | โ$40.5M | โ$73.0M | โ$93.6M | โ$101M | โ$99.9M | โ$144M |
| Depreciation and amortization | $0.6M | $1.4M | $2.5M | $3.5M | $3.5M | $2.9M |
| Stock-based compensation | $1.3M | $4.3M | $10.7M | $13.4M | $9.8M | $18.9M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Balance sheet | ||||||
| Cash and short-term investments | $48.5M | $207M | $230M | $137M | $91.9M | $455M |
| Current assets | $49.1M | $214M | $237M | $141M | $96.5M | $458M |
| Current liabilities | $10.2M | $10.2M | $13.1M | $15.6M | $18.6M | $25.2M |
| Property and equipment, net | $4.7M | $6.9M | $12.6M | $10.1M | $6.6M | $0.5M |
| Total assets | $75.9M | $243M | $299M | $198M | $143M | $464M |
| Total liabilities | $27.6M | $26.3M | $48.8M | $47.4M | $46.2M | $628M |
| Shareholders' equity | โ$59.1M | $216M | $251M | $151M | $96.7M | โ$164M |
| Returns | ||||||
| Return on capital employed | โ66.0% | โ29.7% | โ32.6% | โ69.0% | โ97.5% | โ84.7% |
| Return on equity | โ | โ87.7% | โ39.5% | โ58.7% | โ94.5% | โ |
| Return on assets | โ57.1% | โ43.3% | โ34.0% | โ47.4% | โ68.6% | โ229.3% |
| Return on tangible equity | โ | โ32.4% | โ36.7% | โ78.2% | โ120.9% | โ |
| Growth | ||||||
| Share count change | โ | 15,544.9% | 18.3% | 69.9% | โ94.9% | 187.3% |
| Financial health | ||||||
| Current ratio | 4.8x | 21.1x | 18.1x | 9.0x | 5.2x | 18.2x |
| Quick ratio | 4.8x | 21.1x | 18.1x | 9.0x | 5.2x | 18.2x |
| Quality scores | ||||||
| Altman Z'' | โ5.4 | 10.5 | 5.8 | โ2.4 | โ10.4 | โ7.6 |
| Accruals ratio | โ9.3% | 0.2% | โ2.6% | โ7.1% | โ10.1% | โ182.3% |
Source: SEC EDGAR XBRL filings (CIK 0001817229). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.